[Toxicity and antimicrobial properties of the new aminoglycoside antibiotic 535].
LD50 of antibiotic 535 (3'-desoxykanamycin C) on its intravenous, subcutaneous and oral administration to albino mice was 225, 1150 and at least 5000 mg/kg respectively. After a single subcutaneous administration to rabbits in a dose of 10 mg/kg antibiotic 535 was rapidly absorbed and detected in the blood and organs of the animals for 24 hours. The antibiotic was mainly excreted with the urine. Comparative investigation of the pharmacokinetics of antibiotic 535, tobramycin and kanamycin in rabbits revealed no significant differences. Antibiotic 535 showed a broad antibacterial spectrum and inhibited both grampositive and gramnegative bacteria. It was highly active against infections caused by S. aureus, E. coli and Pr. vulgaris and somewhat less active against infections caused by Ps. aeruginosa. In treatment of experimental tuberculosis of albino mice antibiotic 535 and tobramycin were inferior by their efficacy to kanamycin.
D000617:Aminoglycosides / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*; D001424:Bacterial Infections / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D007612:Kanamycin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D007700:Kinetics; D007928:Lethal Dose 50; D051379:Mice; D011817:Rabbits; D013997:Time Factors; D014031:Tobramycin / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D014376:Tuberculosis / Q000188:drug therapy
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D007612:Kanamycin; C047737:3'-deoxykanamycin C; D014031:Tobramycin
Izuchenie toksichnosti i antimikrobnykh svoĭstv novogo aminoglikozidnogo antibiotika 535.